Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04094844 · ClinicalTrials.gov registry record · NA
Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation
A NA study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 372
- Enrollment target
NCT04094844: Completed NA study, sponsored by University of Michigan Rogel Cancer Center.
NCT04094844 is a NA study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 372 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04094844, a NA study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 372 participants
- Enrollment target
Study Summary
The purpose of this research study is to measure the effects of using a mobile phone app (Roadmap 2.0) on the health-related quality of life of caregivers and patients undergoing allogeneic/autologous hematopoietic cell transplantation (HCT).
Primary Outcome
Mean Global Health scores for each arm at day 120. PROMIS® instruments are scored using item-level calibrations. This method of scoring uses "response pattern scoring," which uses responses to each item for each participant. Scores generally range from 20 to 80, with higher scores indicating better health.
Interventions
- OTHER Survey administration
- BEHAVIORAL Roadmap 2.0 information system
- OTHER Wearable activity sensor
- BEHAVIORAL Roadmap 2.0 information system with Positive Activities
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2020-09-08 |
| Est. Completion | 2024-08-11 |
| Phase | NA |
What the finished NCT04094844 record still lists
NCT04094844 is an interventional study that assigns participants to a tested intervention. The registered 372 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 4 interventions - of which Survey administration is the first listed.
NCT04094844 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04094844 about?
NCT04094844 is a clinical study titled "Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation". The purpose of this research study is to measure the effects of using a mobile phone app (Roadmap 2.0) on the health-related quality of life of caregivers and patients undergoing allogeneic/autologous hematopoietic cell transplantation (HCT).
What is the current status of trial NCT04094844?
This trial is currently completed. It is a NA study. The enrollment target is 372 participants. The study started on 2020-09-08. Estimated completion is 2024-08-11.
What interventions are being tested in trial NCT04094844?
The interventions under investigation include: Survey administration (OTHER), Roadmap 2.0 information system (BEHAVIORAL), Wearable activity sensor (OTHER), Roadmap 2.0 information system with Positive Activities (BEHAVIORAL).
Who is sponsoring clinical trial NCT04094844?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04094844's enrollment target sits among peer trials
372 280th of 2000 higher than 1,720 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- NCT05318105 · 372 participants · NA
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
- NCT06797635 · 372 participants · Phase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI